Parion Sciences, Inc.
Paul Boucher, President
919-475-9600
[email protected]
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors
Parion plans to initiate Phase 2 studies of P-1037 for the treatment of cystic fibrosis in the second half of 2014
Durham, NC (April 30, 2014) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it has reached an agreement with Gilead Sciences, Inc. to reacquire the rights to epithelial sodium channel (ENaC) inhibitors identified and developed under a research collaboration announced between the parties in 2007. Gilead is eligible to receive future undisclosed royalties based upon the commercial success of select compounds.
During their collaboration, the companies made significant advances in the discovery and characterization of potential compounds that inhibit ENaC, leading to the selection of the clinical stage compound P-1037/GS-5737.